[The Efficacy of Bismuth-containing Quadruple Therapy after Moxifloxacin-based Sequential Therapy Failure in Helicobacter pylori Eradication].

Background/aims: Moxifloxacin-based sequential therapy showed an excellent eradication rate as the first line treatment of () infection. However, to the best of our knowledge, there were only a few studies on the treatment of those with failed moxifloxacin-based sequential therapy. Hence, this study was to investigate the efficacy of bismuth-containing quadruple therapy in those with failed moxifloxacin-based sequential or reverse sequential therapy for eradication.

[The Prevalence of Nontuberculous Mycobacterial Lung Disease with orwithout Reflux Esophagitis].

Background/aims: Gastrointestinal reflux disease (GERD) is defined as 'a condition that develops when the reflux of stomach contents causes troublesome symptoms and/or complications'. It is associated with various lung diseases, including bronchial asthma, chronic bronchitis, and bronchiectasis. GERD may also affect nontuberculous mycobacterial (NTM) lung disease.

[The Efficacy of Moxifloxacin-containing Triple Therapy after Hybrid Therapy Failure in Eradication].

Background/aims: Hybrid therapy was successful in eradicating () according to previous reports. However, to the best of our knowledge, there have only been a few studies evaluating the optimal choice after hybrid failure. Hence, we aimed to evaluate the efficacy of moxifloxacin-containing triple therapy after hybrid therapy failure in eradication.

Rifabutin-based Fourth and Fifth-line Rescue Therapy in Patients with for Eradication Failure.

Background/aims: Optimized regimen has not yet been established for failures of multiple () eradication. Hence, we aimed to evaluate the efficacy of rifabutin-based rescue therapy, at least after three eradication failures.

Methods: Twelve patients, who failed in the treatment for eradication at least three times, were consecutively enrolled between 2007 and 2015 at Seoul National University Bundang Hospital.

Cerebral venous thrombosis in a patient with Crohn's disease.

Patients with inflammatory bowel disease (IBD) have an elevated risk of venous thromboembolism compared with the general population. The most common sites of venous thromboembolism in IBD patients are the deep veins of the legs, the pulmonary system, and portal and mesenteric veins. However, cerebral venous thrombosis is rarely associated with IBD.